What is HC Wainwright’s Forecast for Climb Bio Q1 Earnings?

Climb Bio, Inc. (NASDAQ:CLYM) – Investment analysts at HC Wainwright decreased their Q1 2026 earnings per share estimates for shares of Climb Bio in a report issued on Tuesday, March 10th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.28) for the quarter, down from their previous estimate of ($0.18). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Climb Bio’s current full-year earnings is ($1.57) per share. HC Wainwright also issued estimates for Climb Bio’s Q2 2026 earnings at ($0.31) EPS, Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($1.08) EPS and FY2027 earnings at ($1.18) EPS.

CLYM has been the subject of a number of other reports. Raymond James Financial initiated coverage on shares of Climb Bio in a research report on Tuesday. They issued a “strong-buy” rating for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Climb Bio in a research report on Wednesday, January 21st. Piper Sandler began coverage on Climb Bio in a research note on Friday, February 13th. They issued an “overweight” rating on the stock. Robert W. Baird upped their target price on Climb Bio from $9.00 to $12.00 and gave the company an “outperform” rating in a report on Friday, March 6th. Finally, Wedbush started coverage on Climb Bio in a research report on Thursday, March 5th. They set an “outperform” rating and a $12.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Climb Bio currently has an average rating of “Moderate Buy” and a consensus price target of $11.40.

Climb Bio Price Performance

Shares of CLYM stock opened at $7.33 on Thursday. The firm has a 50-day moving average of $5.39 and a 200-day moving average of $3.43. Climb Bio has a one year low of $1.05 and a one year high of $8.04. The company has a market cap of $499.79 million, a P/E ratio of -8.24 and a beta of -0.25.

Climb Bio (NASDAQ:CLYM) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.06).

Institutional Investors Weigh In On Climb Bio

Several large investors have recently modified their holdings of CLYM. Nan Fung Trinity HK Ltd. purchased a new position in Climb Bio in the second quarter valued at approximately $575,000. Prelude Capital Management LLC bought a new position in Climb Bio during the third quarter valued at $82,000. Balyasny Asset Management L.P. purchased a new stake in Climb Bio in the fourth quarter worth $57,000. Marshall Wace LLP purchased a new stake in Climb Bio in the second quarter worth $46,000. Finally, Qube Research & Technologies Ltd bought a new stake in shares of Climb Bio in the second quarter valued at $43,000. Hedge funds and other institutional investors own 69.76% of the company’s stock.

Insiders Place Their Bets

In related news, Director Ra Capital Management, L.P. purchased 101,462 shares of Climb Bio stock in a transaction that occurred on Friday, December 12th. The stock was bought at an average price of $2.86 per share, for a total transaction of $290,181.32. Following the completion of the transaction, the director owned 3,396,318 shares in the company, valued at $9,713,469.48. This represents a 3.08% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 0.80% of the company’s stock.

Key Headlines Impacting Climb Bio

Here are the key news stories impacting Climb Bio this week:

• Positive Sentiment: HC Wainwright raised its price target on CLYM from $11 to $15 and kept a “Buy” rating — a large upside vs. the current share price, which is likely the main bullish catalyst for the stock today. Benzinga Article
• Neutral Sentiment: HC Wainwright published quarterly EPS estimates for FY2027 (Q1: -$0.26, Q2: -$0.29, Q3: -$0.31, Q4: -$0.32) and a full‑year consensus of about -$1.57. These are model-driven projections that reaffirm expected losses but also provide a roadmap for investor expectations. MarketBeat Report
• Negative Sentiment: Reports flagged a “large increase” in March short interest, but the published figures show 0 shares and NaN changes with a 0.0 days-to-cover — indicating likely data/reporting errors. If confirmed as a real short build, it could add downward pressure; as-is, the ambiguity may fuel volatility and speculative trading.

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.